ENTYVIO PEN Drug Profile

Summary for Tradename: ENTYVIO PEN

High Confidence Patents:	4
Applicants:	1
BLAs:	1

Pharmacology for ENTYVIO PEN

Mechanism of Action	Integrin Receptor Antagonists
Established Pharmacologic Class	Integrin Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ENTYVIO PEN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ENTYVIO PEN Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO PEN	vedolizumab	Injection	761133			DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO PEN	vedolizumab	Injection	761133			DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO PEN	vedolizumab	Injection	761133			DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO PEN	vedolizumab	Injection	761133			DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ENTYVIO PEN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO PEN	vedolizumab	Injection	761133		2036-07-20	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO PEN	vedolizumab	Injection	761133		2032-05-02	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO PEN	vedolizumab	Injection	761133		2036-08-10	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO PEN	vedolizumab	Injection	761133		2036-07-20	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO PEN	vedolizumab	Injection	761133		2035-06-23	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO PEN	vedolizumab	Injection	761133		2036-06-14	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO PEN	vedolizumab	Injection	761133		2038-01-08	Patent claims search

Market Dynamics and Financial Trajectory for ENTYVIO PEN

Last updated: February 19, 2026

What is the market position of ENTYVIO PEN?

ENTYVIO PEN (vedolizumab) is a subcutaneous formulation introduced in 2023 for the treatment of inflammatory bowel diseases (IBD) — specifically Crohn’s disease and ulcerative colitis. Developed by Takeda Pharmaceutical, it is an alternative to the intravenous (IV) formulation, aiming to improve patient compliance and convenience.

How does ENTYVIO PEN compare to existing therapies?

Feature	ENTYVIO PEN	Infusion-based ENTYVIO	Competing Biologics (Adalimumab, infliximab)
Administration	Subcutaneous injection (single dose)	IV infusion (every 8 weeks)	Subcutaneous (adalimumab) / IV (infliximab)
Dosing Frequency	Every 8 weeks after induction	Every 8 weeks	Varies by drug, often bi-weekly or monthly
Pricing (2023)	Approx. $4,600 per dose	Approx. $4,300 per infusion	$2,500 – $6,000 per dose depending on drug

What is the market size for ENTYVIO PEN?

The global IBD treatment market was valued at approximately $10.2 billion in 2022. The biologics segment accounts for roughly 80% of this value, driven by the demand for targeted therapies like vedolizumab. The subset for vedolizumab (including ENTYVIO PEN) is estimated at $2.5 billion, with growth projections at a compound annual growth rate (CAGR) of 6% through 2028.

Penetration estimates

• The IV form holds 70% of market share within vedolizumab products.
• ENTYVIO PEN aims for a 20–25% share within vedolizumab use by 2025.
• The overall IBD biologic market is forecasted to reach $15 billion by 2028, with ENTYVIO PEN contributing an estimated $600 million in revenue globally by 2026.

What factors influence ENTYVIO PEN’s market share?

Key Growth Drivers

• Convenience: Transition from IV to subcutaneous administration increases adherence.
• Patient preference: Reduced clinic visits; home administration.
• Competitive pricing: Slight premium over IV, justified by convenience.
• Regulatory approval: U.S. FDA approved ENTYVIO PEN in Q2 2023; European agencies followed by Q4 2023.

Barriers to Adoption

• Physician inertia: Preference for established infusion protocols.
• Payer policies: Reimbursement challenges may delay uptake.
• Cost considerations: Higher drug costs compared to older biologics.

Competitive landscape

Competitors	Market Position	Strengths	Weaknesses
Adalimumab	Top-selling biologic	Established efficacy	Frequent injections
Infliximab	Widely used in hospitals	Long track record	IV administration
Ustekinumab	Growing in popularity	Longer dosing intervals	Cost

What is the financial trajectory outlook?

Revenue projections

• Estimated peak sales of ENTYVIO PEN: ~$600 million globally by 2026.
• U.S. market share in IBD biologics: ~30% by 2028.
• Price point: $4,600 per dose, assuming a 50% gross margin.

Cost considerations

• R&D and marketing spend: $200 million annually through 2025.
• Manufacturing costs: Approximately 20% of revenue.
• Break-even point expected around 2024, with profitability by 2025.

Investment implications

• Takeda’s total IBD portfolio (including ENTYVIO) revenue is projected to grow at a CAGR of 8% through 2028.
• ENTYVIO PEN expansion is a key driver, representing roughly 15% of the global vedolizumab sales by 2028.
• Increased adoption may be influenced by health insurance coverage policies, with early adoption favored by patient preference for home dosing.

What are the regulatory and pricing policies influencing growth?

• FDA: Approved ENTYVIO PEN in June 2023 under a priority review pathway.
• Pricing policies: U.S. CMS and private insurers are likely to negotiate rebates, affecting net revenue.
• European agencies: Likely approval by Q4 2023, facilitating regional growth.

Key potential risks

• Competition from biosimilars of other biologics, such as adalimumab.
• Slow uptake due to clinician or payer resistance.
• Reimbursement challenges limiting access.

Key Takeaways

• ENTYVIO PEN captures a niche segment in the IBD biologics market, driven by ease of administration.
• The global market for vedolizumab is projected to reach $3 billion by 2028.
• Revenue growth hinges on market acceptance, payer coverage, and competitive dynamics.
• Takeda’s strategic focus on expanding the subcutaneous form influences its long-term financial outlook.

FAQs

1. How does ENTYVIO PEN’s pricing compare with the IV formulation?
It is approximately $300 more per dose, reflecting convenience and home use benefits.

2. What is the expected timeline for market penetration?
Significant adoption is anticipated to begin in 2024, reaching about 25% of vedolizumab use by 2025.

3. How does patient demand influence commercialization?
Patients favor subcutaneous injections for convenience, especially in outpatient or home settings, promoting faster uptake.

4. What are the main competitive advantages of ENTYVIO PEN?
Ease of use, reduced clinic visits, and improved patient adherence.

5. What regulatory challenges could affect growth?
Delays or restrictions in approval outside the U.S. and Europe could slow expansion.

References

1. Bloomberg Intelligence. (2023). Biologic Drugs Market Data.
2. IQVIA. (2023). Global Biologics Market Report.
3. FDA. (2023). FDA approval documents for ENTYVIO PEN.
4. Takeda Pharmaceutical. (2023). Corporate Annual Report.
5. MarketsandMarkets. (2023). Inflammatory Bowel Disease Drugs Market Forecast.